
What smart money is saying about Elanco Animal Health, Inc.
2 funds in our archive have pitched Elanco Animal Health, Inc. — most recently Hardman Johnston Global Equity in December 2025.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Fund coverage · 2 theses
- Hardman Johnston Global EquityDecember 2025
Elanco Animal Health, Inc. is shifting toward higher-margin companion animals with multiple potential blockbusters and deleveraging supporting a strategic turnaround.
Read the full thesis - Baron Health Care FundDecember 2025
Elanco Animal Health Incorporated is at an inflection with an accelerating innovation portfolio driving growth, margin expansion, and deleveraging.
Read the full thesis
Read every full thesis on Elanco Animal Health, Inc.
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→